Camrelizumab, formerly known as SHR-1210, represents a significant advancement in tumor immunotherapy , functioning as a monoclonal that targets the Camrelizumab programmed death-1 receptor. This checkpoint protein, expressed on lymphocytes , normally restrains anti-tumor immune responses, allowing tumor cells to evade recognition by the body’s i